Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTXD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Galera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Galera Therapeutics's regulatory disclosures and financial reporting.
Ikarian Capital, LLC and Neil Shahrestani filed Amendment No. 1 to a Schedule 13G regarding Galera Therapeutics, Inc. common stock. The amendment reports that the Reporting Persons now have beneficial ownership of 0.00 shares and 0% of the class, with no sole or shared voting or dispositive power over any Galera Therapeutics shares.
The filing explains that a fund and certain separately managed accounts advised by Ikarian Capital are the record owners of the securities previously covered, and details how investment discretion is exercised. Each party, including the fund and the managed accounts, disclaims beneficial ownership of the other’s shares and also disclaims being part of a group for purposes of Section 13(d) or 13(g).